tbuckley/cabot-search huggingface dataset:
OS-013 Targeting the histamine receptor 2 for HCC chemoprevention
Authors: Emilie Crouchet, Courtney Katz, Naoto Fujiwara, Frank Jühling, Marine Oudot, Sarah Durand, Antonio Saviano, Romain Martin, Fabio Giannone, Patrick Pessaux, Raymond Chung, Catherine Schuster, Laurent Mailly, Yujin Hoshida, Thomas Baumert
Journal: Journal of Hepatology (2024)
OS-014-YI Long-term albumin infusion reduces the mortality of cirrhosis and ACLF animal models by modulating the gut-liver axis and hepatic TLR4 signalling
Authors: Alexandra Phillips, Qianwen Zhao, Abeba Habtesion, Fausto Andreola, Nathan Davies, Lindsey Edwards, Jane Macnaughtan, Sabine Klein, Jonel Trebicka, Rajiv Jalan
Journal: Journal of Hepatology (2024)
OS-090 Novel epigenetic editing technology targets hepatitis B virus in vivo to deeply and durably repress viral markers
Authors: Yesseinia Anglero-Rodriguez, Sahar Abubucker, John Xiong, Jhon Medina, Caroline Mugambwa, Rayman Choo-wing, Carrietta Jacques, Glen Acosta, Scott Clarkson, Kendra Bayne, Mary Morrison, Ari Friedland, Narayan Wong, Zohan Hoque, Amber DiPiazza, Parthu Koppana, Kuo-Chan Hung, Sameer Abraham, Adam Zhai, Pietro Spinelli, Vic Myer, Aron Jaffe
Journal: Journal of Hepatology (2024)
OS-117 Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial
Authors: Jörn M Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Stephen A. Harrison, Mazen Noureddin
Journal: Journal of Hepatology (2024)
FRI-338 Obeticholic acid promotes the hepatic ductular reaction via hepatocyte-mediated HMGB1 by disrupting autophagosomelysosome fusion in cholestasis
Authors: Jie Wang, Qianhui Tang, Weishuang Shen, Qingyu Chen, Qinwei Yu, Luyong Zhang, Zhenzhou Jiang
Journal: Journal of Hepatology (2024)
LBP-020 A phase 1, double-blinded, randomized, placebo-controlled, multicenter global study evaluating the safety, tolerability, and antiviral activity of DF-006 in chronic hepatitis B, virologicallysuppressed patients
Authors: Edward J. Gane, Eshwari Kovoor, Alina Jucov, Igor Anastasiy, Marta Dobryanska, Susan Parker, Carl Cook, Cong Xu, Tian Xu, Henri Lichenstein, Jeysen Yogaratnam
Journal: Journal of Hepatology (2024)
OS-089-YI Transgenerational maternal obesity induces mitochondrial dysfunction and aggravates MASLD, which can be reversed by metabolic drug candidates
Authors: Anneleen Heldens, Milton Antwi, Louis Onghena, Lindsey Devisscher, Xavier Verhelst, Sarah Raevens, Hans Van Vlierberghe, Ruth de Bruyne, Anja Geerts, Sander Lefere
Journal: Journal of Hepatology (2024)
OS-049-YI The anti-tumour effector function of mucosal-associated invariant T cells against hepatocellular carcinoma is impaired by fatty acids and aberrant lipid metabolism
Authors: Sebastian Deschler, Junika Pohl, Lukas Ramsauer, Philippa Meiser, Robin P. Schenk, H. Carlo Maurer, Juliane Kager, Sophia Erlacher, Joseph Zink, Karyna Pistrenko, Enric Redondo Monte, Julius Weber, Fabian Geisler, Douglas Thorburn, Gabriela M. Wiedemann, Karin Kleigrewe, Carolin Mogler, Jan P. Böttcher, Percy A. Knolle, Roland M. Schmid, Katrin Böttcher
Journal: Journal of Hepatology (2024)
OS-042-YI Metabolic reprogramming induced by pravastatin prevents polycystic liver disease progression improving mitochondrial bioenergetics in cystic cholangiocytes
Authors: Enara Markaide, Laura Izquierdo-Sánchez, Mikel Ruiz de Gauna, Xabier Buque, Pedro M Rodrigues, Rui E. Castro, Matxus Perugorria, Luis Bujanda, Patricia Aspichueta, Jesus M Banales
Journal: Journal of Hepatology (2024)
OS-108-YI Liver lymphatic endothelial cells regulate hepatic progenitor cells via lymphangiocrine factors in pathological liver regeneration
Authors: Aarti Sharma, Pinky Juneja, Ashwini Vasudevan, Deepika Jakhar, Jayesh Kumar Sevak, Impreet Kaur, Shiv Kumar Sarin, Dinesh Mani Tripathi, Savneet Kaur
Journal: Journal of Hepatology (2024)
LBP-027 Combined effect of obeticholic acid and bezafibrate in patients with primary biliary cholangitis and inadequate response or intolerance to ursodeoxycholic acid: 6-month results from a phase 2 trial
Authors: David E. Jones, Alexandre Louvet, Christophe Corpechot, Vaclav Hejda, Heng Zou, Antonio Civitarese, Alejandra Villamil, Frederik Nevens
Journal: Journal of Hepatology (2024)
Neuro‐Immunomodulatory Potential of Nanoenabled 4D Bioprinted Microtissue for Cartilage Tissue Engineering
Authors: Marina Couto, Daniela Pereira Vasconcelos, Catarina Leite Pereira, Estrela Neto, Bruno Sarmento, Meriem Lamghari
Journal: Advanced Healthcare Materials (2024)

Cartilage defects trigger post-traumatic inflammation, leading to a catabolic metabolism in chondrocytes and exacerbating cartilage degradation. Current treatments aim to relieve pain but fail to target the inflammatory process underlying osteoarthritis (OA) progression. Here, a human cartilage microtissue (HCM) nanoenabled with ibuprofen-loaded poly(lactic-co-glycolic acid) nanoparticles (ibu-PLGA NPs) is 4D-bioprinted to locally mitigate inflammation and impair nerve sprouting. Under an in vitro inflamed environment, the nanoenabled HCM exhibits chondroprotective potential by decreasing the interleukin (IL)1β and IL6 release, while sustaining extracellular matrix (ECM) production. In vivo, assessments utilizing the air pouch mouse model affirm the nanoenabled HCM non-immunogenicity. Nanoenabled HCM-derived secretomes do not elicit a systemic immune response and decrease locally the recruitment of mature dendritic cells and the secretion of multiple inflammatory mediators and matrix metalloproteinases when compared to inflamed HCM condition. Notably, the nanoenabled HCM secretome has no impact on the innervation profile of the skin above the pouch cavity, suggesting a potential to impede nerve growth. Overall, HCM nanoenabled with ibu-PLGA NPs emerges as a potent strategy to mitigate inflammation and protect ECM without triggering nerve growth, introducing an innovative and promising approach in the cartilage tissue engineering field.
Superimposed Electric Field Enhanced Electrospray for High‐Throughput and Consistent Cell Encapsulation
Authors: Zejun Fan, Yihan Chen, Zhen Yang, Yudi Niu, Kaini Liang, Yan Zhang, Jianan Zeng, Yiting Feng, Yuying Zhang, Ye Liu, Cheng Lv, Peng Zhao, Lv Zhou, Wenyu Kong, Wenjing Li, Haoke Chen, Dongbo Han, Yanan Du
Journal: Advanced Healthcare Materials (2024)

Abstract Cell encapsulation technology, crucial for advanced biomedical applications, faces challenges in existing microfluidic and electrospray methods. Microfluidic techniques, while precise, can damage vulnerable cells, and conventional electrospray methods often encounter instability and capsule breakage during high‐throughput encapsulation. Inspired by the transformation of the working state from unstable dripping to stable jetting triggered by local electric potential, this study introduces a superimposed electric field (SEF)‐enhanced electrospray method for cell encapsulation, with improved stability and biocompatibility. Utilizing stiffness theory, we quantitatively analyze the stability of the electrospray, whose stiffness is five times stronger under conical confinement. The SEF technique enabled rapid, continuous production of ∼300 core‐shell capsules per second in an aqueous environment, significantly improving cell encapsulation efficiency. Our method demonstrated remarkable potential as exemplified in two key applications: 1) a 92‐fold increase in human‐derived induced pluripotent stem cells (iPSCs) expansion over 10 days, outperforming traditional 2D cultures in both growth rate and pluripotency maintenance, and 2) the development of liver capsules for steatosis modeling, exhibiting normal function and biomimetic lipid accumulation. The SEF‐enhanced electrospray method presents a significant advancement in cell encapsulation technology. It offers a more efficient, stable, and biocompatible approach, opening new possibilities in clinical transplantation, drug screening, and cell therapy. This article is protected by copyright. All rights reserved
Janus Amphipathic Dressing With Liquid Self‐Pumping and Blood‐Clot Anti‐Adhesion for Satisfactory Hemostasis
Authors: Qiao Yu, Wenjie Wang, Ningyue Deng, Baihai Su, Weifeng Zhao, Changsheng Zhao
Journal: Advanced Healthcare Materials (2024)

Abstract Ideal hemostatic materials for the emergency rescue of war and traffic accident sufferers are essential to significantly control hemorrhage, reduce patient discomfort, and improve the survival ratio. However, most hemostats absorb blood quickly in contact with the wound; and then, adhere to blood clots, resulting in breaking scabs and tearing the wound when the materials are removed. Herein, an effective Janus amphipathic hemostatic dressing (Fiber@Gel/Ca 2+ /KL) with a fiber layer (polylactic acid/carboxymethyl chitosan) and a hydrogel layer (polyvinyl alcohol, carboxymethyl chitosan, Ca 2+ , and kaolin) is reported. Such a composite dressing unidirectionally drains the excessive serum from its hydrophobic side (fiber layer) to its hydrophilic side (hydrogel layer), so‐called self‐pumping, thereby further concentrating coagulated factors (including red blood cells and platelets). Further, Ca 2+ diffused from the hydrogel layer subsequently activates platelets and coagulation cascade. Besides, the Fiber@Gel/Ca 2+ /KL exhibits specific blood‐clot anti‐adhesion property on the fiber layer, making the dressing easily and safely peel off from the wound. It is believed that this novel hemostatic dressing with good hemostatic performance, easy clots removal, and excellent biocompatibility is expected to be used as a safe and efficient hemostatic dressing in clinical applications.
Mobilizing Endogenous Progenitor Cells Using pSDF1α‐Activated Scaffolds Accelerates Angiogenesis and Bone Repair in Critical‐Sized Bone Defects
Authors: Rosanne M. Raftery, Arlyng G. Gonzalez Vazquez, David P. Walsh, Gang Chen, Ashang L. Laiva, Michael B. Keogh, Fergal J. O'Brien
Journal: Advanced Healthcare Materials (2024)

Abstract Mobilizing endogenous progenitor cells to repair damaged tissue in situ has the potential to revolutionize the field of regenerative medicine, while the early establishment of a vascular network will ensure survival of newly generated tissue. In this study, a gene‐activated scaffold containing a stromal derived factor 1α plasmid (pSDF1α), a pro‐angiogenic gene that is also thought to be involved in the recruitment of mesenchymal stromal cells (MSCs) to sites of injury is described. It is shown that over‐expression of SDF1α protein enhanced MSC recruitment and induced vessel‐like structure formation by endothelial cells in vitro. When implanted subcutaneously, transcriptomic analysis reveals that endogenous MSCs are recruited and significant angiogenesis is stimulated. Just 1‐week after implantation into a calvarial critical‐sized bone defect, pSDF1α‐activated scaffolds are recruited MSCs and rapidly activate angiogenic and osteogenic programs, upregulating Runx2 , Dlx5 , and Sp7 . At the same time‐point, pVEGF‐activated scaffolds are recruited a variety of cell types, activating endochondral ossification. The early response induced by both scaffolds leads to complete bridging of the critical‐sized bone defects within 4‐weeks. The versatile cell‐free gene‐activated scaffold described in this study is capable of harnessing and enhancing the body's own regenerative capacity and has immense potential in a myriad of applications.
Initial therapeutic evidence of a borosilicate bioactive glass (BSG) and Fe3O4 magnetic nanoparticle scaffold on implant-associated Staphylococcal aureus bone infection
Authors: Ying Jin, Hang Liu, Lei Chu, Jin Yang, Xiuyang Li, Hang Zhou, Haitao Jiang, Lei Shi, Jason Weeks, Joshua Rainbolt, Changjiang Yang, Thomas Xue, Haobo Pan, Zhongliang Deng, Chao Xie, Xu Cui, Youliang Ren
Journal: Bioactive Materials (2024)
Therapeutic Potential of Lipoprotein(a) Inhibitors
Authors: Stephen J. Nicholls
Journal: Drugs (2024)

Increasing evidence has implicated lipoprotein(a) [Lp(a)] in the causality of atherosclerosis and calcific aortic stenosis. This has stimulated immense interest in developing novel approaches to integrating Lp(a) into the setting of cardiovascular prevention. Current guidelines advocate universal measurement of Lp(a) levels, with the potential to influence cardiovascular risk assessment and triage of higher-risk patients to use of more intensive preventive therapies. In parallel, considerable activity has been undertaken to develop novel therapeutics with the potential to achieve selective and substantial reductions in Lp(a) levels. Early studies of antisense oligonucleotides (e.g., mipomersen, pelacarsen), RNA interference (e.g., olpasiran, zerlasiran, lepodisiran) and small molecule inhibitors (e.g., muvalaplin) have demonstrated effective Lp(a) lowering and good tolerability. These agents are moving forward in clinical development, in order to determine whether Lp(a) lowering reduces cardiovascular risk. The results of these studies have the potential to transform our approach to the prevention of cardiovascular disease.
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer
Authors: Yiran Liang, Fangzhou Ye, Dan Luo, Li Long, Yajie Wang, Yuhan Jin, Lei Wang, Yaming Li, Dianwen Han, Bing Chen, Wenjing Zhao, Lijuan Wang, Qifeng Yang
Journal: Molecular Cancer (2024)

Abstract Background Breast cancer is the most common malignant tumor, and metastasis remains the major cause of poor prognosis. Glucose metabolic reprogramming is one of the prominent hallmarks in cancer, providing nutrients and energy to support dramatically elevated tumor growth and metastasis. Nevertheless, the potential mechanistic links between glycolysis and breast cancer progression have not been thoroughly elucidated. Methods RNA-seq analysis was used to identify glucose metabolism-related circRNAs. The expression of circSIPA1L3 in breast cancer tissues and serum was examined by qRT-PCR, and further assessed its diagnostic value. We also evaluated the prognostic potential of circSIPA1L3 by analyzing a cohort of 238 breast cancer patients. Gain- and loss-of-function experiments, transcriptomic analysis, and molecular biology experiments were conducted to explore the biological function and regulatory mechanism of circSIPA1L3. Results Using RNA-seq analysis, circSIPA1L3 was identified as the critical mediator responsible for metabolic adaption upon energy stress. Gain- and loss-of-function experiments revealed that circSIPA1L3 exerted a stimulative effect on breast cancer progression and glycolysis, which could also be transported by exosomes and facilitated malignant behaviors among breast cancer cells. Significantly, the elevated lactate secretion caused by circSIPA1L3-mediated glycolysis enhancement promoted the recruitment of tumor associated macrophage and their tumor-promoting roles. Mechanistically, EIF4A3 induced the cyclization and cytoplasmic export of circSIPA1L3, which inhibited ubiquitin-mediated IGF2BP3 degradation through enhancing the UPS7-IGF2BP3 interaction. Furthermore, circSIPA1L3 increased mRNA stability of the lactate export carrier SLC16A1 and the glucose intake enhancer RAB11A through either strengthening their interaction with IGF2BP3 or sponging miR-665, leading to enhanced glycolytic metabolism. Clinically, elevated circSIPA1L3 expression indicated unfavorable prognosis base on the cohort of 238 breast cancer patients. Moreover, circSIPA1L3 was highly expressed in the serum of breast cancer patients and exhibited high diagnostic value for breast cancer patients. Conclusions Our study highlights the oncogenic role of circSIPA1L3 through mediating glucose metabolism, which might serve as a promising diagnostic and prognostic biomarker and potential therapeutic target for breast cancer.
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Authors: Carlo Lombardi, Pasquale Comberiati, Erminia Ridolo, Marcello Cottini, Mona Rita Yacoub, Silvia Casagrande, Matteo Riccò, Marco Bottazzoli, Alvise Berti
Journal: Drugs (2024)

Monoclonal antibodies targeting interleukin (IL)-5 pathways have revolutionized the treatment expectations for eosinophilic-associated conditions, particularly in patients with respiratory involvement. Mepolizumab (IL-5 antagonist monoclonal antibody), benralizumab (IL-5 receptor blocker monoclonal antibody), and reslizumab (IL-5 antagonist monoclonal antibody) have collectively contributed to the overall improvement of the disease burden in various conditions. Eosinophilic asthma currently boasts the most robust evidence across all age groups: all three biologics are approved for adults (aged ≥18 years); mepolizumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) also in children (aged ≥ 6 years), while bernalizumab was recently approved by the FDA for patients aged ≥6 years in the USA. In chronic rhinosinusitis with nasal polyps, subcutaneous mepolizumab is the only anti-IL-5 therapy approved so far and can be used in adult patients (aged ≥18 years). For eosinophilic esophagitis, conflicting evidence surrounds both mepolizumab, reslizumab, and benralizumab, leading to non-approval of these agents by the FDA/EMA. Recently, mepolizumab was approved for eosinophilic granulomatosis with polyangiitis patients aged ≥6 years or older and for hypereosinophilic syndrome adult patients. A phase III trial proving noninferiority of benralizumab versus mepolizumab in eosinophilic granulomatosis with polyangiitis has been recently published, while evidence on reslizumab is scant. Overall, current evidence on anti-IL-5 biologics for eosinophilic-associated disorders is mostly focused on adults, whereas data for individuals aged under 18 years and over 65 years are scarce, resulting in a lack of evidence, particularly regarding efficacy, for the use of anti-IL-5 agents in these specific patient populations. This review addresses high-quality evidence from randomized controlled trials and real-world post-marketing studies regarding the use of anti-IL-5 therapies for eosinophilic-associated disorders across all age groups, spanning childhood, adulthood, and older age.
Biomimetic Multilayered Lipid Nanovesicles for Potent Protein Vaccination
Authors: Bon Il Koo, Dong Jae Lee, Rafia Tasnim Rahman, Yoon Sung Nam
Journal: Advanced Healthcare Materials (2024)

Lipid vesicles are widely used for drug and gene delivery, but their structural instability reduces in vivo efficacy and requires specialized handling. To address these limitations, strategies like lipid cross-linking and polymer-lipid conjugation are suggested to enhance stability and biological efficacy. However, the in vivo metabolism of these altered lipids remains unclear, necessitating further studies. A new stabilization technique without chemical modification is urgently needed. Here, a bio-mimetic approach for fabricating robust multilamellar lipid vesicles to enhance in vivo delivery and stabilization of protein antigens is presented. This method leverages 1-O-acylceramide, a natural skin lipid, to facilitate the self-assembly of lipid nanovesicles. Incorporating 1-O-acylceramide, anchoring lipid bilayers akin to its role in the stratum corneum, provides excellent stability under environmental stresses, including freeze-thaw cycles. Encapsulating ovalbumin as a model antigen and the adjuvant monophosphoryl lipid A demonstrates the vesicle's potential as a nanovaccine platform. In vitro studies show enhanced immune responses with both unilamellar and multilamellar vesicles, but in vivo analyses highlight the superior efficiency of multilamellar vesicles in inducing higher antibody and cytokine levels. This work suggests ceramide-induced multilamellar lipid vesicles as an effective nanovaccine platform for enhanced antigen delivery and stability.
Can neurodevelopmental disorders influence the course of neurodegenerative diseases? A scoping review
Authors: Perrine L.M. Siguier, Mélanie Planton, Eloise Baudou, Yves Chaix, Alix Delage, Marie Rafiq, Marie Wolfrum, Fleur Gérard, Mélanie Jucla, Jérémie Pariente
Journal: Ageing Research Reviews (2024)

This scoping review aims at giving an overview of the possible influence of neurodevelopmental disorders (NDDs) on cognitive-behavioral neurodegenerative diseases (CBNDs). Based on the PRISMA-ScR checklist, it details the methods of NDDs screening, the identified NDDs-CBNDs associations, as well as the criteria and types of association. The last literature search was performed in June 2023. In the final study, 32 articles were included. Analysis first showed that NDDs were mainly detected through medical records screening. Second, the association of specific learning disorders and major or mild neurocognitive disorder due to Alzheimer's disease was the most investigated. Third, associations were mostly based on prevalence comparisons. Finally, 66 % of studies reported a positive association between NDDs and CBNDs. Notably, up to 67 % of positive associations were observed with atypical forms of certain CBNDs. Authors' interpretations suggest that NDDs could constitute a risk factor for CBNDs. However, the influence of NDDs on CBNDs still lacks evidence and biological support, possibly due to the heterogeneity of methods and criteria employed. Developing validated assessment tools for all NDDs and conducting cohort studies could be beneficial for research, and clinical practice. Indeed, this review also underlines the importance of adopting a life-span approach regarding CBNDs.
Multi-detector fusion and Bayesian smoothing for tracking viral and chromatin structures
Authors: C. Ritter, J.-Y. Lee, M.-T. Pham, M.K. Pabba, M.C. Cardoso, R. Bartenschlager, K. Rohr
Journal: Medical Image Analysis (2024)

Automatic tracking of viral and intracellular structures displayed as spots with varying sizes in fluorescence microscopy images is an important task to quantify cellular processes. We propose a novel probabilistic tracking approach for multiple particle tracking based on multi-detector and multi-scale data fusion as well as Bayesian smoothing. The approach integrates results from multiple detectors using a novel intensity-based covariance intersection method which takes into account information about the image intensities, positions, and uncertainties. The method ensures a consistent estimate of multiple fused particle detections and does not require an optimization step. Our probabilistic tracking approach performs data fusion of detections from classical and deep learning methods as well as exploits single-scale and multi-scale detections. In addition, we use Bayesian smoothing to fuse information of predictions from both past and future time points. We evaluated our approach using image data of the Particle Tracking Challenge and achieved state-of-the-art results or outperformed previous methods. Our method was also assessed on challenging live cell fluorescence microscopy image data of viral and cellular proteins expressed in hepatitis C virus-infected cells and chromatin structures in non-infected cells, acquired at different spatial-temporal resolutions. We found that the proposed approach outperforms existing methods.